|
Xanthus Life Sciences, Inc. |
|
|
300 Technology Square
Cambridge, MA 02139 USA
phone: 617-225-0522
fax: 617-225-0525
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.Xanthus.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Oncology drug development. |
|
| Management |
| Richard T. Dean, PhD; Chief Executive Officer; Robert L. Capizzi, MD; Senior Vice President, Chief Medical Officer; Robert Boisjoli, CA, CBV; Chief Financial Officer; Alfred M. Ajami, PhD; Chief Scientific Officer; Michael A. Boss, PhD, MBA; Chief Business Officer; John Lister-James, PhD; Vice President, Development; J. Kris Piper; Vice President, Clinical Operations & Regulatory Affairs |
| |
|
|
| |
|
| Keywords |
| oncology, small molecule, Xanafide, Symadex, Clomet, |
|
|
|
| Description |
|
Xanthus is an oncology drug development company with a number of small molecules advancing in clinical development for multiple cancer indications. |
|
| Products / Services |
Xanthus' small molecule candidates are Xanafide, Symadex, and Clomet which are advancing in clinical and preclinical development for multiple cancer indications. Each of these product candidates was in-licensed based on significant clinical and/or preclinical data supporting safety and activity.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members